Intrabodies: Turning the humoral immune system outside in for intracellular immunization

Gene Therapy

Volumn 4, Issue 1, 1997, Pages 11-15

  Marasco, W A ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

AIDS; Antibody engineering; Gene therapy; Intracellular antibodies; Oncogenes

Indexed keywords

ANTIBODY; CELL PROTEIN; GROWTH FACTOR RECEPTOR; INTRABODY; ONCOPROTEIN; UNCLASSIFIED DRUG;

ANTIGEN BINDING; BINDING AFFINITY; BINDING SITE; CANCER THERAPY; CLINICAL PROTOCOL; DRUG TARGETING; GENE THERAPY; GENETIC ENGINEERING; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; INFECTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SHORT SURVEY; VIRUS INHIBITION; VIRUS REPLICATION;

MAMMALIA;

EID: 0031016269     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3300346     Document Type: Short Survey

References (61)

1. Burton DR et al. A large array of human monoclonal antibodies to type 1 human immunodeficiency virus from combinatorial libraries of asymptomatic sero-positive individuals Proc Natl Acad Sci USA 1991; 88: 10134-10137.
2. Hoogenboom HR, Marks JD, Griffiths AD, Winter G. Building antibodies from their genes. Immunol Rev 1992; 130: 41-68.
3. Winter G, Griffiths AD, Hawkins RE, Hoogenboom HR. Making antibodies by phage display technology. Annu Rev Immunol 1994; 12: 433-455.
4. Marks JD, Hoogenboom HR, Griffiths AD, Winter G. Molecular evolution of proteins on filamentous phage: mimicking the strategy of the immune system. J Biol Chem 1992; 267: 16007-16010.
5. Nissim A et al. Antibody fragments from a 'single pot' phage display library as immunochemical reagents. EMBO J 1994; 13: 692-698.
6. Vaughan TJ et al. Human antibodies with sub-nanomolar affinities isolated from a large non-immunized phage display library. Nature Bio 1996; 14: 309-314.
7. Marks C, Marks JD. Phage libraries - a new route to clinically useful antibodies. New Engl J Med 1996; 335: 730-733.
8. Portolano S, McLachlan SM, Rapoport B. High affinity, thyroid-specific human autoantibodies displayed on the surface of filamentous phage use V genes similar to other autoantibodies. J Immunol 1993; 151: 2839-2851.
9. Barbas SM et al. Human autoantibody recognition of DNA. Proc Natl Acad Sci USA 1995; 92: 2529-2533.
10. Barbas CF III et al. Recombinant human Fab fragments neutralize human type 1 immunodeficiency virus in vitro. Proc Natl Acad Sci USA 1992; 89: 9339-9343.
11. Zebedee SL et al. Human combinatorial antibody libraries to hepatitis B surface antigen. Proc Natl Acad Sci USA 1992; 89: 3175-3179.
12. Lonberg N et al. Antigen-specific human antibodies from mice comprising four distinct genetic modifications. Nature 1994; 368: 856-859.
13. Green IX et al. Antigen-specific human monoclonal antibodies from mice engineered with human Ig heavy and light chain YACs. Nat Genet 1994; 7: 13-21.
14. Marasco WA. Intracellular antibodies (intrabodies) as research reagents and therapeutic molecules for gene therapy. Immuno-technology 1995; 1: 1-19.
15. Richardson JH, Marasco WA. Intracellular antibodies: development and therapeutic potential. Trends Biotech 1995; 13: 306-310.
16. Biocca S, Cattaneo A. Intracellular immunization: antibody targeting to subcellular compartments. Trends Cell Biol 1995; 5: 248-252.
17. Mhashilkar AM et al. Inhibition of HIV-1 Tat-mediated LTR transactivation and HIV-1 infection by anti-Tat single chain intrabodies. EMBO J 1995; 14 1542-1551.
18. Chen S-Y, Khouri Y, Bagley J, Marasco WA. Combined intra- and extracellular immunization against human immunodeficiency virus type 1 infection with a human anti-gp120 antibody. Proc Natl Acad Sci USA 1994; 91: 5932-5936.
19. Maciejewski JP et al. Intracellular expression of antibody fragments directed against HIV reverse transcriptase prevents HIV infection m vitro. Nat Mag 1995; 1: 667-673.
20. Chen J et al. Intra- and extra-cellular immunization against HIV-1 infection with lymphocytes transduced with an AAV vector expressing a human anti-gp120 antibody gene. Hum Gene Ther 1996; 7: 1515-1525.
21. Levin R et al. Inhibition of early and late events of the HIV-1 replication cycle by cytoplasmic Fab intrabodies against the matrix protein, p17. Mol Med 1996 (in press).
22. Biocca S et al. Redox state of single chain Fv fragments targeted to the endo-plasmic reticulum, cytosol and mitochondria. Biotechnology 1995; 13: 1110-1115.
23. Marasco WA, Haseltine WA, Chen SY. Design, intracellular expression, and activity of a human anti-human immunodeficiency virus type 1 gp120 single-chain antibody. Proc Natl Acad Sci USA 1993; 90: 7889-7893.
24. Jost CR et al. Mammalian expression and secretion of functional single-chain Fv molecules. J Biol Chem 1994; 269: 26267-26273.
25. Richardson JH, Sodroski JG, Waldmann TA, Marasco WA. Phenotypic knockout of the high-affinity human interleukin 2 receptor by intracellular single-chain antibodies against the α subunit of the receptor. Proc Natl Acad Sci USA 1995; 92: 3137-3141.
26. Richardson JH et al. Phenotypic knockout of the interleukin-2 receptor in HTLV-I transformed cell lines JAIDS 1995; 10: 246.
27. Graus-Porta D, Beerli RR, Hynes NE. Single-chain antibody- mediated intracellular retention of ErbB-2 impairs Neu differentiation factor and epidermal growth factor signaling. Mol Cell Biol 1995; 15: 1182-1191.
28. Slamon DJ et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989; 244: 707-713.
29. Natali PG et al. Expression of the p185 encoded by HER2 oncogene in normal and transformed human tissues. Int J Cancer 1990; 45: 457-461.
30. Hung M-C et al. Aberrant expression of the c-erbB-2/neu protooncogene in ovarian cancer. Cancer Lett 1992; 61: 95-103.
31. Hynes NE. Amplification and overexpression of the erbB-2 gene in human tumors: its involvement in tumor development, significance as a prognostic factor, and potential as a target for cancer therapy. Cancer Biol 1993; 4: 19-26.
32. Beerli RR, Wels W, Hynes NE. Intracellular expression of single chain antibodies reverts ErbB-2 transformation. J Biol Chem 1994; 269: 23931-23936.
33. Deshane J et al. Intracellular single-chain antibody directed against erbB2 down-regulates cell surface erbB2 and exhibits a selective anti-proliferative effect in erbB2 overexpressing cancer cell lines. Gene Therapy 1994; 1: 332-337.
34. Deshane J et al. Targeted eradication of ovarian cancer mediated by intracellular expression of anti-erbB-2 single-chain antibody. Gyn Oncol 1995; 59: 8-14.
35. Deshane J et al. Targeted tumor killing via an intracellular antibody against erbB-2. J Clin Invest 1995; 96: 2980-2989.
36. Adams GP, Weiner LM. Intracellular single-chain Fv antibodies - a knockout punch for neoplastic cells? Gyn Oncol 1995; 59: 6-7.
37. ras single chain Fv fragments inhibits meiotic maturation of xenopus oocytes. Biochem Biophy Res Comm 1993; 197: 422-427.
38. Biocca S, Pierandrei-Amaldi P, Campioni N, Cattaneo A. Intracellular immunization with cytosolic recombinant antibodies. Bio/Technology 1994; 12: 396-399.
39. Werge TM, Baldari CT, Telford JL. Intracellular single chain Fv antibody inhibits Ras activity in T-cell antigen receptor stimulated Jurkat cells. FEBS Lett 1994; 351: 393-396.
40. ras scFv a model for anti-tumor therapy. Exploring and Exploiting Antibody and Ig Superfamily Combining Sites. Keystone Symposia, New Mexico, 22-28 February 1996, p 46.
41. Montano X, Jimenez A. Intracellular expression of the monoclonal anti-ras antibody Y13-259 blocks the transforming activity of ras oncogenes. Cell Growth Differ 1995; 6: 597-605.
42. Poul M-A, Teyssier C, Lefranc M-P. Inhibition of cyclin D1 oncogene with intracellular single chain antibodies. Exploring and Exploiting Antibody and Ig Superfamily Combining Sites. Keystone Symposia, New Mexico, 22-28 February 1996.
43. Jiang W, Venugopal K, Gould EA. Intracellular interference of tick-borne flavivirus infection by using a single-chain antibody fragment delivered by recombinant sindbis virus. J Virol 1995; 69: 1044-1049.
44. Marasco WA. Using intracellular antibodies (intrabodies) for research and gene therapy applications. Program and abstracts of the Gene Therapy of Cancer, AIDS and Genetic Disorders, International Symposium, International Centre for Genetic Engineering and Biotechnology, 10-13 April, 1996, Trieste, Italy. (Abstr.)
45. Poznansky MC et al. Intracellular antibodies against Tat and gp120 inhibit the replication of HIV-1 in T-cells from HIV-infected individuals. Xth International AIDS Conference, Vancouver, 1996 (Abstr.).
46. Jones SD et al. Gene therapy for HIV using intracellular antibodies. J Cell Bio 1995; 21A: 395.
47. Mhashilkar AB, Agarwal S, Levin R, Marasco WA. Genetic-based strategies for control of HIV-1: Tat and Rev as potential targets. Drug News Perspect 1996; 9: 220-227.
48. Duan L et al. Potent inhibition of human immunodeficiency virus type 1 replication by an intracellular anti-Rev single-chain antibody. Proc Natl Acad Sci USA 1994; 91: 5075-5079.
49. Duan L, Zhu M, Bagasra O, Pomerantz RJ. Intracellular immunization against HIV-1 infection of human T lymphocytes: utility of anti-rev single-chain variable fragments. Hum Gene Ther 1995; 6: 1561-1573.
50. Wu Y et al. Binding of intracellular anti-Rev single chain variable fragments to different epitopes of human immunodeficiency virus type 1 Rev: variations in virol inhibition. J Virol 1996; 70: 3290-3297.
51. Choo V. Combination superior to zidovudine in Delta trial. Lancet 1995; 346: 895.
52. Collier AC et al. Extended treatment with saquinavir (SAQ), zidovudine (ZDV), and zalcitabine (ddc) vs SAQ and ZDV vs ddc and ZDV. In: Program and Abstracts of the 35th Interference Conference on Antimicrobial Agents and Chemotherapy. San Francisco, 17-20 September 1995. Washington: 1995; American Society for Microbiology (Abstr. 236).
53. Collier AC et al. Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. New Engl J Med 1996; 334: 1011-1017.
54. Feng Y, Broder CC, Kennedy PE, Berger EA. HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science 1996; 272: 872-877.
55. Deng HK et al. Identification of a major co-receptor for primary isolates of HIV-1 Nature 1996; 381: 661-666.
56. + cells is mediated by the chemokine receptor CC-CKR-5. Nature 1996; 381: 667-673.
57. Choe H et al. The β-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. Cell 1996; 85: 1135-1148.
58. Doranz BJ et al. A dual-tropic primary HIV-1 isolate that uses fusin and the β-chemokine receptors CKR-5, CKR-3, and CKR-2b as fusion cofactors. Cell 1996; 85: 1149-1158.
59. Barr PJ, Tomei LD. Apoptosis and its role in human disease. Bio/Technology 1994; 12: 487-493.
60. Pantaleo G, Fauci AS. Apoptosis in HIV infection. Nat Med 1995; 1: 118-120.
61. Thompson CB. Apoptosis in the pathogenesis and treatment of disease. Science 1995; 267: 1456-1462.